Skip to content 
EBOO therapy for poor circulation is one of the few topics in the EBOO conversation with direct clinical evidence. Unlike most EBOO claims that rely on ozone therapy research in general, the only controlled EBOO trial ever published focused specifically on circulation.
But the evidence tells a more nuanced story than most clinics share. The Di Paolo 2005 trial showed that EBOO produced significantly better tissue healing in patients with peripheral artery disease. However, it did so without a measurable increase in arterial blood flow itself.
That distinction matters. EBOO therapy for poor circulation may help your tissues heal better and receive more oxygen, but not by pumping more blood through your vessels. The benefit appears to come from improved oxygenation, reduced inflammation, and enhanced tissue repair. This guide explains what that means for you in practical terms.
If you are new to EBOO, start with what EBOO therapy is. This article focuses specifically on circulation.
Poor circulation is not a diagnosis. It is a symptom of an underlying condition, most commonly peripheral artery disease (PAD), diabetes, Raynaud’s phenomenon, or chronic venous insufficiency.
The signs are familiar. Cold hands and feet even when the room is warm. Numbness or tingling in your extremities. Slow wound healing, especially on legs and feet. Leg pain or cramping when you walk. Skin discoloration. Swelling in your lower legs.
Conventional treatment addresses the underlying cause: medications to manage cholesterol and blood pressure, blood thinners, exercise programs, and in advanced cases, surgical interventions like angioplasty or bypass grafting.
But many patients continue to experience poor circulatory symptoms despite treatment. The underlying disease may be managed, but tissue oxygenation remains compromised. This gap is where some patients begin exploring EBOO therapy for poor circulation as a complementary approach.
EBOO therapy for poor circulation proposes to help through three pathways. The strength of evidence varies for each, but all three are relevant to circulation.
This is the most important mechanism for circulation patients, and it is also the most commonly misunderstood.
Ozone increases the production of 2,3-diphosphoglycerate (2,3-DPG) in red blood cells. 2,3-DPG helps release oxygen from hemoglobin into tissues. More 2,3-DPG means your existing blood delivers more oxygen per pass through your vessels.
This is critical. You do not need more blood flow to get more oxygen to your tissues. You need each red blood cell to release its oxygen more efficiently. That is what ozone’s effect on 2,3-DPG achieves.
This mechanism explains the Di Paolo trial results. Patients had better tissue healing without increased arterial blood flow because their blood delivered oxygen more effectively, not because it flowed faster.
Chronic circulatory problems are often made worse by thick, viscous blood that flows poorly through narrowed or damaged vessels. Ozone therapy has been shown to improve blood rheology by increasing red blood cell flexibility.
More flexible red blood cells can squeeze through narrowed capillaries more easily, delivering oxygen to tissues that thickened blood cannot reach. This is particularly relevant for patients with microvascular disease, where the smallest blood vessels are the most compromised.
Chronic inflammation drives vascular disease. Inflamed blood vessel walls narrow the space available for blood flow, and inflammatory debris circulating in the blood contributes to plaque formation and tissue damage.
Ozone’s documented NF-kB suppression reduces pro-inflammatory cytokine production. EBOO adds the filtration component that physically removes inflammatory proteins, oxidized lipids, and debris from the blood during the session.
The full inflammation mechanism is explained in EBOO therapy for chronic inflammation: how it works and what the evidence shows.
This is where EBOO therapy for poor circulation has a genuine advantage over every other EBOO topic. The only controlled clinical trial studying EBOO specifically involved patients with circulation issues.
The 2005 trial enrolled 28 patients with peripheral artery disease and compared EBOO to intravenous prostacyclin, which was the standard treatment at the time. The EBOO group showed significantly greater regression of skin lesions, improvements in pain, and better overall wellbeing.
No serious adverse events were reported. The treatment appeared safe across the study population.
But the trial also found no measurable change in arterial blood flow. This nuance separates honest providers from those who overclaim. EBOO did not open arteries or increase blood flow through vessels. The benefit came from somewhere else, likely the oxygenation, viscosity, and anti-inflammatory mechanisms described above.
The trial was also small (28 patients), came from a single research group in Italy, and has not been independently replicated. These limitations are real and matter.
The complete study breakdown is in EBOO therapy research and clinical evidence.
EBOO therapy for poor circulation will not open blocked arteries. If you have significant arterial occlusion, you may need angioplasty, stenting, or bypass surgery. EBOO cannot replace these interventions.
EBOO will not cure peripheral artery disease, diabetes, or any other condition causing your poor circulation. It is a complementary approach that may support tissue oxygenation and healing alongside your existing treatment.
EBOO will not replace blood thinners, cholesterol medications, or blood pressure medications prescribed by your vascular specialist. Never adjust your prescribed medications based on EBOO results without consulting your doctor.
For the full contraindication screening, read EBOO therapy contraindications: who should not have it.
EBOO therapy for poor circulation usually makes the most sense for patients diagnosed by a vascular specialist with an established treatment plan. The best candidates have persistent circulatory symptoms despite conventional treatment, particularly slow wound healing, cold extremities, or limited walking tolerance.
Patients with peripheral artery disease are the most directly relevant population because the Di Paolo trial studied them. Patients with diabetic circulatory complications, Raynaud’s, or chronic venous insufficiency may also benefit, but the evidence is extrapolated, not direct.
At Purefico Medspa and Longevity Center in Cornelius, NC, we require that circulation patients have a current diagnosis and an established relationship with a vascular specialist before beginning EBOO. Do not pursue this therapy before you have been properly evaluated.
Circulation patients are often on medications that require careful coordination with EBOO. Anticoagulants like warfarin, heparin, or newer blood thinners need close monitoring because EBOO itself involves heparin in the circuit. Your EBOO provider must know exactly what you are taking.
Antiplatelet medications like aspirin or clopidogrel are common in PAD patients. These generally do not prevent EBOO, but your provider needs to know about them.
Disclose vasodilators and blood pressure medications because ozone may have mild vasodilatory effects in some patients.
The bottom line: bring your complete medication list to your consultation. Do not assume any medication is irrelevant.
The full safety profile is covered in ” Is EBOO therapy safe? What the evidence actually shows.
Circulation is the one area where I can point to EBOO-specific evidence rather than extrapolating from ozone research in general. That makes me more comfortable discussing EBOO for this purpose than for many others.
But I also need to be clear about what the evidence actually showed. It showed better healing and less pain, not more blood flow. That distinction matters because some patients come in expecting EBOO to open their arteries, and the research doesn’t support that. I would rather set honest expectations and exceed them than overpromise and disappoint.
If you have been diagnosed with poor circulation and conventional treatment has not fully resolved your symptoms, book a consultation with our team. We will review your diagnosis, coordinate with your vascular specialist, and give you an honest assessment of whether EBOO could add value.
You can also read: Is EBOO therapy worth it? An honest look at cost, results, and evidence, or learn about
our EBOO therapy service in Cornelius, NC.
EBOO therapy for poor circulation may improve circulatory outcomes like tissue healing and pain reduction without necessarily increasing blood flow volume. The Di Paolo 2005 trial showed these benefits in patients with peripheral artery disease. The improvement likely comes from better tissue oxygenation, reduced inflammation, and improved blood viscosity rather than from increased arterial blood flow.
The only EBOO clinical trial found no measurable increase in arterial blood flow. However, it did find significantly better tissue healing, which suggests the benefit comes from improved oxygen delivery per red blood cell rather than increased blood volume flowing through vessels. This is an important distinction.
EBOO uses heparin in the blood circuit, so patients on anticoagulants require careful coordination. EBOO is not automatically contraindicated for patients on blood thinners, but your provider must review your complete medication list and adjust the protocol accordingly. Never start EBOO without disclosing all medications.
Most practitioners recommend at least three sessions to assess response, typically one to two weeks apart. The Di Paolo trial used multiple sessions over several weeks. Your provider should evaluate your response at the three-session mark and adjust the plan accordingly.
EBOO processes more blood per session and includes filtration that standard ozone therapy lacks. For circulation patients specifically, the Di Paolo trial studied EBOO, not standard ozone therapy. Whether this makes EBOO objectively better for circulation has not been compared in a head-to-head trial.
No. EBOO is classified as experimental and elective. Insurance does not cover it for any condition, including peripheral artery disease. A typical course of three to six sessions costs between $750 and $4,800 out of pocket.
No. EBOO therapy for poor circulation is an adjunct therapy. It cannot replace angioplasty, stenting, bypass surgery, or prescribed vascular medications. If your vascular specialist recommends a procedure, EBOO is not an alternative. It may complement conventional treatment, not replace it.
Yes. Purefico Medspa and Longevity Center in Cornelius, near Charlotte, offers EBOO therapy for patients with circulatory concerns. We require a consultation, a vascular specialist diagnosis, and a full medication review before beginning sessions.
1. Di Paolo N, Bocci V, Salvo DP, et al. Extracorporeal blood oxygenation and ozonation (EBOO): a controlled trial in patients with peripheral artery disease. International Journal of Artificial Organs. 2005;28(10):1039-1050.
2. Di Paolo N, Bocci V, Garosi G, et al. Extracorporeal blood oxygenation and ozonation (EBOO) in man. Preliminary report. International Journal of Artificial Organs. 2000;23(2):131-141.
3. Bocci V, Zanardi I, Travagli V. Ozone acting on human blood yields a hormetic dose-response relationship. Journal of Translational Medicine. 2011;9:66.
4. Bocci V. Scientific and medical aspects of ozone therapy: state of the art. Archives of Medical Research. 2006;37(4):425-435.
5. Viebahn-Haensler R, Leon Fernandez OS. Ozone in medicine: low-dose ozone in chronic inflammatory diseases. International Journal of Molecular Sciences. 2021;22(15):7890.
6. U.S. Food and Drug Administration. 21 CFR 801.415, Maximum acceptable level of ozone.
Melissa Lynch, NP, is a nurse practitioner with 28 years of clinical experience and the founder of Purefico MedSpa & Therapy, with locations in Cornelius and Archdale, North Carolina.
